Kornimate/medical-research-clean huggingface dataset:
diurnal curves with bimatoprost 0.03% versus travoprost 0.004%

Conditions: Glaucoma

Summary: to compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * · male or female \> 18 years of age * naive to treatment or washed off any ocular hypotensive agents * untreated iop \>19 mm hg * diagnosis of open-angle glaucoma or ocular hypertension * ability to provide informed consent and likely to complete study exclusion criteria: * · known contraindication to bimatoprost or travoprost, or any component of any study medication * uncontrolled systemic disease * active ocular disease other than glaucoma or ocular hypertension * required use of ocular medications other than the study medications during the study * history of intraocular surgery within the last 3 months * prior discontinuation of any of the study medications for reasons related to efficacy or safety
coronavirus (covid-19) diagnostic lung ultrasound study

Conditions: COVID-19

Summary: this observational study is designed to assess whether focused lung ultrasound examination can improve the diagnosis of covid-19 lung disease and/or make an alternative diagnosis at a patient's initial hospital presentation. for patients with confirmed covid-19 the study will also assess whether surveillance lung ultrasound examination can predict clinical outcome over the course of their hospital admission.

study participants will be screened from and recruited on their entry into the suspected covid-19 admission pathway at derriford hospital, plymouth, uk. in addition to usual clinical care (including physical exam and observations, blood tests, nasopharyngeal swab for viral pcr testing, and chest x-ray as standard), participants will undergo focused lung ultrasound examination. participants who are negative for covid-19 will be followed up to confirm their final discharge diagnoses, and clinical outcome at either 3 months post-enrolment or discharge from hospital. participants who are positive for covid-19 will have regular focused lung ultrasound examination during their hospital admission in addition to usual clinical care until their treatment for covid-19 is complete. their discharge diagnoses and clinical outcome at either 3 months post-enrolment or discharge from hospital (whichever is later).

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * suspected or confirmed diagnosis of covid-19 * able to provide informed consent to study participation exclusion criteria: * age less than 18 years * inability to provide informed consent at the time of study enrolment

Keywords: covid-19 lung ultrasound
age-related macular degeneration, scotopic dysfunction, and driving performance in a simulator

Conditions: Age-related Macular Degeneration

Summary: previous work collectively suggests that rod-mediated dark adaptation (rmda) is a promising candidate as a functional endpoint measure for evaluating interventions to slow early progression of age-related macular degeneration (amd). however, there is no agreement among the clinical, research and regulatory communities as to what constitutes a clinically (practically) significant slowing in rmda. treatments for amd are often not considered efficacious if they do not result in a criterion level of improvement in vision. but how much change in the rate of dark adaptation constitutes a clinically significant change? until this issue is resolved, progress in developing clinical trials on early amd are at a standstill since there is no functional endpoint to be used in the trial. one approach to establishing clinical significance is to examine how rmda relates to the performance of an everyday visual task under low luminance conditions, such as night driving or reading. however, such data are not yet available. the purpose of this project is to examine the relationship between rmda and night-time driving and reading under poor illumination. this information will guide the development of a definition of a clinically significant difference in rmda that can be used in designing clinical trials on early amd.

the specific aims of this study are as follows: aim 1: to examine the association between rmda as assessed by the rod intercept time and self reported driving difficulty and experiences during night time driving. aim 2: to examine the association between rmda as assessed by rod intercept time and reading performance as assessed by the mnread test administered under a low light level. reading performance will be defined in terms of maximum reading speed, critical print size (i.e., the smallest print size that supports maximum reading speed), reading acuity (i.e., the smallest print size that can be just read) and the reading accessibility index (i.e., an individual's access to text over the range of print sizes found in everyday life).

Eligibility criteria:
inclusion criteria: * age-related macular degeneration in one or both eyes, ability to follow simple instructions, licensed to drive a vehicle, can read and speak english exclusion criteria: * diabetes, retinal or optic nerve conditions other than age-related macular degeneration, neurological conditions that impair vision

Keywords: age-related macular degeneration
ph ii osi-774 (erlotinib,tarceva) in advanced bronchioloalveolar cell lung cancer

Conditions: Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer

Summary: the primary objective of this study is to determine the major objective response rate of osi-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer. this study is a phase ii study. the first study of osi-774 was done to evaluate what dose should be given to patients with cancer has been completed. the purpose of this research study is to see whether this experimental treatment, called osi-774, can cause a type of non-small cell lung cancer to stop growing or shrink. this study is sponsored by a company called genentech, and is being done at memorial hospital, as well as other cancer centers around the country interested in developing new drugs for the treatment of this type of cancer.


Eligibility criteria:
inclusion criteria: * either bronchioloalveolar cell carcinoma or a variant thereof after review * clinical stage iiib (malignant pleural or pericardial effusion) or iv or recurrent/medically inoperable disease * measurable or evaluable indicator lesions * no prior or one chemotherapy regimen for nsclc * three weeks since last chemotherapy, and three weeks since prior radiation therapy to a major bone-marrow containing area * karnofsky performance status \> or = to 80% or ecog performance status ≤ or = to 1 * life expectancy \> or = to 8 weeks * adequate hematologic, renal and/or hepatic function: wbc \> or = to 3,000/ul, hemoglobin \> or = to 9.0 g/dl, platelet count \> or = to 100,000/ul, total bilirubin \ or = to 55ml/min. * effective contraception exclusion criteria: * prior exposure to osi-774 or other treatments targeting the her family axis (e.g.-trastuzumab, zd1839, c225, etc.) * two or more prior chemotherapy regimens * concurrent active cancer * uncontrolled central nervous system metastases (i.e. any known cns lesion which is radiographically unstable, symptomatic and/or requiring escalating doses of corticosteroids) * pregnant or lactating women * malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * prior systemic cytotoxic chemotherapy for other malignant disease * significant medical history or unstable medical condition (unstable systemic disease: congestive heart failure, recent mi, unstable angina, active infection, uncontrolled hypertension).

Keywords: non small cell lung cancer
to compare to 2-channel and multiple-channel single port laparoscopic-assisted vaginal hysterectomy

Conditions: Myoma; Adenomyosis

Summary: the main objective of this trial is to assess the efficacy and safety of single port-access laparoscopic-assisted vaginal hysterectomy. the operative time, weight of the uterus, blood loss and hospital stay will be record, respectively. the pain score is based on the visual analogue scale in which patients record the intensity of their pain 12, 24, and 48 hours after surgery.

single port laparoscopy is an attempt to further enhance the cosmetic benefits of minimally invasive surgery while minimizing the potential morbidity associated with multiple incisions. preliminary advances in less as applied to urologic and gastrointestinal surgery demonstrate that the techniques are feasible provided that both optimal surgical technical expertise with advanced skills and optimal instrumentation are available. recently, lee et al. performed the multiple channel single port-access laparoscopic-assisted vaginal hysterectomy (spa-lavh) in 24 patient. all cases but 3 were performed exclusively through a single port. the median operative time, weight of the uterus, and estimated blood loss were 119 minutes (range 90 to 255 minutes), 347 g (range 225 to 732 g), and 400 ml (range 100 to 1000 ml), respectively. the median hospital stay (postoperative day) was 3 days (range 3 to 7). although there are a limited number of studies demonstrating the feasibility of single-port access laparoscopic-assisted vaginal hysterectomy (lavh), single-port surgery is "new-old" (i.e., a revisited and unstandardized technique) because the major disadvantage of limited movement caused by collisions of the laparoscopic instruments has been mitigated by the development of multi-channel approaches. therefore, the investigators used a 2-channel single-port system, which was different from the previously published 3-channel single-port technique11,12 to reduce collisions and aid the assistant in controlling the scope without interfering with the surgeon's instruments. to our knowledge, there are no randomize control trial to evaluate of 2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders. the purpose of this study was to assess the feasibility of 2-channel and multiple-channel single port laparoscopy in the treatment of benign uterine disease.

Eligibility criteria:
inclusion criteria: * patients receive laparoscopic-assisted vaginal hysterectomy (lavh) * american society of anesthesiologists (asa) physical status of patient: classification i-ii exclusion criteria: * the procedure will be required to conversion to laparotomy. * any cardio-vascular diseases. * malignant disease

Keywords: 2-channel single port laparoscopy multiple-channel port laparoscopy
efficacy of genicular block on total knee arthroplasty surgery

Conditions: Total Knee Anthroplasty; Genicular Nerves Block

Summary: the aim of this study is to investigate the postoperative pain relieving effect of preoperative genicular block in total knee arthroplasty surgery. the main questions it aims to answer are: 1. do visual analog scale (vas) scores decrease in patients who underwent geniculate block? 2. does opioid consumption decrease in patients who underwent geniculate block? researchers will compare postoperative pain in patients who received genicular block with those who did not.one group of patients will be administered 0.25% bupivacaine with the geniculate block method. the other group will not undergo any intervention. both groups will be administered intravenous morphine for postoperative analgesia.

patients scheduled for knee arthroplasty will be randomly assigned into two groups. one group will receive a genicular nerve block prior to surgery without the administration of general anesthesia, while the other group will not undergo any interventional procedure. the genicular nerve block will be administered in three quadrants around the knee, with each injection consisting of 5 ml of 0.25% marcaine. all injections will be performed by investigator ma. patient assessments will be conducted by investigator mo. postoperative intravenous analgesia will be provided to both groups.

Eligibility criteria:
inclusion criteria: * scheduled for unilateral and primary total knee arthroplasty * older than 18 years of age exclusion criteria: * younger than 18 years * bilateral knee arthroplasty * revision case of knee arthroplasty

Keywords: total knee arthroplasty genicular block postoperative pain
diuretic efficacy of dexamethasone in heart failure

Conditions: Heart Failure, Congestive

Summary: the purpose of this study is to determine whether glucocorticoids have potent diuretic effects in patients with congestive heart failure.

glucocorticoids are known to have pronounced physiological effects in the kidney. conventional teaching dictates that it should be used with caution in patients with congestive heart failure due to its fluid and sodium retention effects. surprisingly, despite the widespread prevalence of this belief within the medical community, there are few data to support it. in fact, several small animal studies have documented its striking diuretic effects due to increased renal plasma flow and glomerular filtration rate without changes in the glomerular filtration fraction. we design this study to determine whether glucocorticoids have a potent diuretic effect in patients with heart failure.

Eligibility criteria:
inclusion criteria: * congestive heart failure patients due to any cause * patients with normal cortical function * congestive heart failure patients who are on diuretic therapy * clinically stable and body weight maintained the same for at least 3 days without signs of fluid retention exclusion criteria: * patient refusal * signs of infection

Keywords: dexamethasone, diuretic, congestive heart failure
spt screening in irradiated hereditary retinoblastoma survivors

Conditions: Retinoblastoma

Summary: rationale: hereditary retinoblastoma survivors have an increased risk to develop second primary tumors (spt) at a later age (with the highest risk in their teens), especially when they have been irradiated for retinoblastoma. the investigators hypothesize that regular screening with magnetic resonance imaging (mri) could lead to early detection of spts leading to improved survival. objective: to evaluate the potential benefit of craniofacial mri screening for early detection subclinical secondary cancers in patients previously irradiated for hereditary retinoblastoma. study design: prospective multicenter non-invasive screening study. the total study duration will be four years of screening plus five years of follow-up. study population: irradiated hereditary retinoblastoma patients 8-18 years old main study parameters/endpoints: to evaluate the ability of craniofacial mri for early detection of spts, the investigators will determine the sensitivity and specificity of mri at detecting spts in irradiated hereditary retinoblastoma patients. nature and extent of the burden and risks associated with participation, benefit and group relatedness: included patients will undergo yearly craniofacial mri for a period of 4 years. they will also be asked to fill out a psychological burden assessment form each visit. a potential risk of screening might be associated anticipatory anxiety, but screening also could be reassuring for patients and their parents; the investigators are not sure which will outweigh. false-positive results from mri screening could lead to unnecessary further diagnostics leading to possible added anxiety and diagnostics (e.g., biopsies). however, this group of patients have a high risk of developing spts, with poor 5-year survival statistics. early detection and therefore treatment of earlier stage (smaller) tumors, might therefore increase survival of this patient group.


Eligibility criteria:
inclusion criteria: * patients with a history of hereditary retinoblastoma * patients that have been treated with external beam radiotherapy for retinoblastoma * age of patients at the first mr scan: 8 years or older (≥8 years old), but only as soon as the mr scan can be performed without sedation or general anesthesia, and until and including 18 years of age (≤18 years old). exclusion criteria: * mri related exclusion criteria: * claustrophobia * foreign non mr compatible metal objects in the body * foreign incompatible metal objects in or close to the head * exclusion criterium for additional contrast sequences: allergic reaction to contrast administration in the past

Keywords: retinoblastoma second primary tumor screening magnetic resonance imaging
biomarkers of homeopathy in fibromyalgia

Conditions: Fibromyalgia

Summary: the purpose of this study is to evaluate the efficacy of individualized classical homeopathy in treatment of persons with fibromyalgia and to determine the usefulness of electroencephalographic and electrocardiographic measures to serve as markers of differences between active and placebo treatment.


Eligibility criteria:
inclusion criteria: * acr diagnosis of fibromyalgia; * willing to take daily active or placebo liquid remedy under double blind conditions for 6 months, involving daily succussion and dilution of source liquid from a stock bottle; * willingness/ability to comply with dietary and lifestyle restrictions, i.e., no coffee in any form, no comphor or menthol-containing products; no electric blankets, no strong aromatics, no routine vaccinations, no concomitant use of acupuncture, chiropractic, polarity therapy, psychic healing, or magnet therapy; * no dental drilling, mri scans unless emergent; * withhold food or drink 30 mins before/after therapy; * stable conventional care for 2 months prior to entry; * willing to undergo 3 diagnostic physical exams, and to permit videotaping of interview sessions; * willing to fill out questionnaires exclusion criteria: * steroid-dependent medical conditions; * chronic benzodiazepine or anticonvulsant use; * use of tricyclic antidepressants, antihypertensives, and other drugs that alter orthostasis; * pregnancy; * history of seizure disorder or syncope; * life-threatening medical conditions; * current active asthma; * history of anaphylactic shock; * insulin-dependent diabetes; * active suicidal ideation or psychosis.

Keywords: fibromyalgia homeopathy eeg ekg chronic pain
ommaya reservoir placement at the time of biopsy for longitudinal biomarker collection in patients with brain tumors

Conditions: Brain Neoplasms

Summary: this observational trial evaluates the use of ommaya reservoir placed during a biopsy to collect biomarkers longitudinally in patients with brain tumor. a biomarker is a measurable indicator of the severity or presence of the disease state. an ommaya reservoir is a small device that's implanted under the scalp. it allows the doctor to take samples of cerebrospinal fluid (csf) in the future without doing a spinal tap. the identification of biomarkers in csf is rapidly emerging as a promising minimally invasive approach for monitoring tumor growth and response to therapy. in the future, these biomarkers may be used to help determine what treatments could be most effective and how well a tumor has responded to prior therapy. currently, limited long-term access to csf has made it difficult for studies to learn if collecting csf at different points in the treatment process is useful. having an ommaya reservoir placed during a biopsy may allow for longitudinal biomarker collection in patients with brain tumor.


Eligibility criteria:
inclusion criteria: * clinical and radiographic evidence suggesting a diagnosis of a brain tumor * planned biopsy for suspected or previously diagnosed brain tumor as part of routine clinical care at mayo clinic (rochester, minnesota \[mn\]) * willingness of the patient to provide informed consent * patient is willing to have their ommaya sampled on at least 2 future occasions * patients is willing to have csf banked through the neuro-oncology biorepository (requires a separate signature) * adults lacking capacity to consent exclusion criteria: * vulnerable populations including pregnant women, prisoners, and individuals \< 18 years old * patients who are not appropriate candidates for biopsy due to current or past medical history or uncontrolled current illness * prior history of any wound infection * any patient who the surgeon feels is not an optimal candidate for ommaya reservoir placement. such reasons may include, but will not be limited to, surgical anatomy, clinical evidence of immunosuppression, and/or elevated risk of wound infection due to diabetes, smoking history, morbid obesity, or any other concerns
rehabilitation of young patients with rheumatic diseases in a warm climate

Conditions: Rheumatic Diseases

Summary: young patients with rheumatic diseases have challenges different from older patients due to their life situation. it has been reported that they do not have the same benefit from age non-specific rehabilitation in warm climate. this trial will test the effect of a specially adapted version of a rehabilitation program delivered in spain (warm climate) for norwegian young adults aged 20-35 years.


Eligibility criteria:
inclusion criteria: * inflammatory rheumatic disease * self reliant in daily life exclusion criteria: - conditions that might influence ability to fly to spain and participate in rehabilitation in warm climate (unstable heart disease, serious lung disease, chronic open ulcers, serious mental health conditions, alcohol or drug addiction, intolerant of sun and heat)

Keywords: climatotherapy
the oncocamp study

Conditions: Oncology

Summary: the present study is a retrospective-prospective observational and multicentric study aiming to collect data relating to all patients included in the roc platform. all roc centers will be involved in the present study.

the roc platform therefore represents a multicenter database and a growing source of data and information regarding cancer patients in the campania region. the need for multicenter databases is supported by the results obtained with both retrospective and prospective studies. many retrospective studies have led to changes in some of the available guidelines. important advantages of this study include representativeness of the analyzed cohort to all patients with a specific cancer and a large sample size that provides sufficient statistical power to detect differences across different patient groups. the data extracted from the roc have the potential to produce knowledge, to guide decision-making, and to manage more effectively the challenges of fighting cancer in our region. the campania region counts more than 6 million people, and it is characterized by a worst oncological outcome compared to the average data of other italian region: the roc platform has the potential to analyze the effect of a public intervention in the field of oncology care. therefore, the primary aim of this study is to create a retrospective-prospective registry of all cancer patients entering the roc platform and in a gom path describing the primary and secondary endpoints.

Eligibility criteria:
inclusion criteria: * signed informed consent * registration in the roc platform

Keywords: oncological network multidisciplinary oncology groups